<--- Back to Details
First PageDocument Content
Single-domain antibody / Antigen / Immunoglobulin heavy chain / Heavy chain / Symphogen / Heavy-chain antibody / Immune system / Biology / Antibody
Date: 2009-11-03 02:38:02
Single-domain antibody
Antigen
Immunoglobulin heavy chain
Heavy chain
Symphogen
Heavy-chain antibody
Immune system
Biology
Antibody

Add to Reading List

Source URL: www.unica-network.eu

Download Document from Source Website

File Size: 3,10 MB

Share Document on Facebook

Similar Documents

Business / Biotechnology / Economy / Pharmacy / Pharmaceutical industry / Pharmaceuticals policy / Biopharmaceutical / Pharmaceutical industry in India / Novartis / Biosimilar / Boehringer Ingelheim / Teva Pharmaceutical Industries

January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

DocID: 1rlhw - View Document

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

DocID: 1mqfS - View Document

Glycoproteins / Medicine / Symphogen / Biotechnology / Antibody / Genentech / Monoclonal antibody therapy / Polyclonal antibodies / John McCafferty / Immunology / Biology / Immune system

Symphogen Enters into strategic collaboration with Genentech for antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN, Denmark –

DocID: 1aQYq - View Document

Glycoproteins / Medicine / Antibodies / Antigen / Immunoglobulin M / Biotechnology / Symphogen / Polyclonal antibodies / Immune system / Biology / Immunology

PDF Document

DocID: 17pgY - View Document

Ebola / Ebola virus disease / Mononegavirales / Zoonoses / Biologic / Antibody / Virus / Cambridge Antibody Technology / Symphogen / Biology / Medicine / Immune system

FOR  IMMEDIATE  RELEASE     Theraclone  Sciences’  I-­‐STAR™  Technology  Chosen  by  Wellcome  Trust     to  Identify  Therapeutic  Antibodies  Against  Ebol

DocID: 178Az - View Document